Q-omics provides the consensus-scored CDH8 profile across patient tissues and cancer cell-line models. CDH8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDH8 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, CDH8 RNA expression shows 15,292 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CDH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH8 survival associations across molecular data types. CDH8 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH8 RNA expression–survival associations across cancer types. High CDH8 expression shows unfavorable associations in ACC, MESO, KIRP, LAML and OV, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDH8 RNA expression.
This table summarizes CDH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CDH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH8 shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, LIHC, LUSC and THCA. The KIRC box plot shows higher CDH8 RNA expression in tumor versus normal tissue (log2 FC = +0.594, t-test p < 0.001).
This table shows molecular features associated with CDH8 in patient tissues and cancer cell lines. In patient samples, CDH8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
